Metabolic markers of human macular neovascular disease and their applications

Through gas chromatography-time-of-flight mass spectrometry technology and pattern recognition methods, metabolic markers of macular neovascular diseases are identified, which solves the diagnostic problems in the prior art and achieves high-accurate disease diagnosis and risk assessment.

CN111308001BInactive Publication Date: 2024-11-29SHANGHAI FIRST PEOPLES HOSPITAL +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN201910974605.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-10-14
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to accurately diagnose macular neovascular diseases, especially because the pathological changes of these diseases are similar, making it difficult to distinguish imaging examinations.

Method used

Combining gas chromatography-time-of-flight mass spectrometry technology and pattern recognition methods, we identify metabolic markers of macular neovascular diseases, provide new diagnostic and typing methods, and clarify the mechanism of disease occurrence and development.

Benefits of technology

By identifying specific biomarkers, such as L-sorbose, D-tagose and ribonocide, high sensitivity, high specific diagnosis and risk assessment for macular neovascular diseases are achieved, and the diagnosis accuracy is improved sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111308001B_ABST
    Figure CN111308001B_ABST
Patent Text Reader

Abstract

The present invention provides metabolic markers of human macular neovascular disease and their applications. Specifically, the present invention provides a biomarker set, which includes a plurality of metabolic biomarkers, which can be used to assess the risk of macular neovascular disease in a subject to be tested or to diagnose macular neovascular disease in a subject to be tested. The present invention also provides a kit comprising the biomarker set and the application of the biomarker set in the risk assessment and diagnosis of macular neovascular disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to metabolic markers of human macular neovascularization diseases and applications thereof. Background Art

[0002] Macular neovascular diseases are a group of diseases characterized by choroidal neovascularization in the macular area, including age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological high myopia.

[0003] Age-related macular degeneration is the leading cause of blindness in patients over 55 years old. By 2040, it will affect about 1.7 billion people, of which 1.1 billion will be in Asia. The abnormal neovascularization caused by age-related macular degeneration can cause fluid and lipid leakage under the macula, fibrous scar formation, and ultimately lead to severe visual impairment. Polypoidal choroidal vasculopathy is also common in the Asian population and is often considered a subtype of age-related macular degeneration. Its neovascularization is related to an abnormal branching vascular network, and the ends of the blood vessels often have polypoid vascular dilation. Pathological high myopia is more common in East Asian countries and is characterized by abnormal choroidal vessels and enlarged eyeballs. All of the above macular neovascular diseases have similar neovascular pathological changes and can lead to severe visual impairment and irreversible blindness. Therefore, this type of disease has become the focus and difficulty of diagnosis and treatment for ophthalmologists.

[0004] So far, the diagnosis of macular neovascular disease mostly relies on imaging examinations, such as optical coherence tomography (OCT), blood flow OCT (OCTA), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), etc. OCT and OCTA are both non-invasive examinations that can quickly and effectively provide high-definition images of the retina, choroid and even sclera of the fundus; FA and ICGA examinations require intravenous injection of sodium fluorescein or indocyanine green contrast agents into the patient, which are often used to detect the blood circulation of the retina and choroid of the patient's fundus. However, since the pathological changes of macular neovascular disease are very similar, sometimes even if all the above detection methods are used, some diseases are still difficult to accurately diagnose. Therefore, there is an urgent need to find other diagnostic methods for macular neovascular disease.

[0005] Therefore, there is an urgent need in this field to combine gas chromatography-time-of-flight mass spectrometry technology with pattern recognition methods to identify metabolic markers of macular neovascular diseases, provide a new diagnostic and classification method for such diseases, and lay the foundation for further clarifying the occurrence and development mechanism of such diseases. Summary of the invention

[0006] The purpose of the present invention is to combine gas chromatography-time-of-flight mass spectrometry technology with pattern recognition methods to identify metabolic markers of macular neovascular disease, provide a new diagnostic and typing method for such diseases, and lay the foundation for further clarifying the occurrence and development mechanism of such diseases.

[0007] In a first aspect of the present invention, a biomarker panel is provided, wherein the panel comprises two or more biomarkers selected from the group consisting of L-sorbose, D-tagatose and ribonolactone.

[0008] In another preferred embodiment, the biomarker set is used to diagnose macular neovascular disease.

[0009] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, including biomarkers selected from the following group: L-sorbose, D-tagatose, or a combination thereof.

[0010] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, and further includes a biomarker selected from the following group: glycerol, L-2-amino-3-(1-pyrazolyl)propionic acid, 5-hydroxylysine, or a combination thereof.

[0011] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, and further includes a biomarker selected from the following group: ribonucleic acid lactone, petroselinic acid, or a combination thereof.

[0012] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, and further includes a biomarker selected from the following group: hexanoic acid, 4-hydroxyphenylpyruvic acid, L-arabinose, L-glutamate, D-maltose, or a combination thereof.

[0013] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, and further includes a biomarker selected from the following group: pipecolic acid, maleic acid, oleic acid, hypoxanthine, linoleic acid, L-cysteine, or a combination thereof.

[0014] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing AMD disease, and further includes a biomarker selected from Table 1;

[0015] Table 1

[0016]

[0017]

[0018] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, including biomarkers selected from the following group: L-sorbose, ribonucleolactone, or a combination thereof.

[0019] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, and further includes a biomarker selected from the following group: petroselinic acid, D-tagatose, myristic acid, or a combination thereof.

[0020] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, and further includes a biomarker selected from the following group: heptadecanoic acid, L-2-amino-3-(1-pyrazolyl)propionic acid, or a combination thereof.

[0021] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, and also includes biomarkers selected from the following group: α-ketoisovalerate, glycerol, 4-hydroxyphenylpyruvate, D-maltose, phenylpyruvate, 5-hydroxylysine, dodecanoic acid, or a combination thereof.

[0022] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, and further includes biomarkers selected from the following group: palmitic acid, hypoxanthine, linoleic acid, stearic acid, pipecolic acid, pyruvic acid, or a combination thereof.

[0023] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PCV disease, and further includes biomarkers selected from Table 2;

[0024] Table 2

[0025]

[0026] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PM disease, including ribonucleic acid lactone.

[0027] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PM disease, and further includes L-2-amino-3-(1-pyrazolyl)propionic acid.

[0028] In another preferred example, the biomarker set is a biomarker set for diagnosing PM disease, and further includes a biomarker selected from the following group: glycerol, D-maltose, or a combination thereof.

[0029] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PM disease, and also includes biomarkers selected from the following group: pyruvate, hypoxanthine, linoleic acid, palmitic acid, oleic acid, petroselinic acid, stearic acid, maleic acid, or a combination thereof.

[0030] In another preferred embodiment, the biomarker set is a biomarker set for diagnosing PM disease, and further includes biomarkers selected from Table 3;

[0031] Table 3

[0032]

[0033] In another preferred embodiment, the set includes two or more biomarkers selected from the following table:

[0034]

[0035]

[0036] In another preferred embodiment, the set includes biomarkers b1 to b20.

[0037] In another preferred embodiment, the set includes biomarker bm and one or more biomarkers selected from subset X, wherein subset X is composed of biomarkers b1~b(m-1) and biomarkers b(m+1)~b20, m is an integer and 1≤m≤20, preferably 1≤m≤7, and more preferably 1≤m≤5.

[0038] In another preferred embodiment, m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20;

[0039] Wherein, when m is 1, the biomarkers b1 to b(m-1) do not exist;

[0040] When m is 2, the biomarkers b1 to b(m-1) represent biomarker b1;

[0041] When m=any integer from 3 to 20, the subset X consists of biomarkers b1 to b(m-1) and biomarkers b(m+1) to b20;

[0042] When m is 19, the biomarkers b(m+1) to b20 represent biomarker b20;

[0043] When m is 20, the biomarkers b(m+1) to b20 do not exist.

[0044] In another preferred embodiment, the set includes biomarkers b1-b3, and one or more biomarkers selected from subset Y, wherein subset Y consists of biomarkers b4-b20.

[0045] In another preferred embodiment, the set includes biomarkers b1-b2, b4-b6 and one or more biomarkers selected from subset Z, wherein subset Z consists of biomarkers b3, b7-b20.

[0046] In another preferred embodiment, the set includes biomarkers b1-b7 and one or more biomarkers selected from subset Z, wherein subset Z consists of biomarkers b8-b20.

[0047] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0048] b1-b7.

[0049] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0050] b1-b2, b4-b6.

[0051] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0052] b1-b3.

[0053] In another preferred embodiment, the set includes biomarkers b1, b3 and one or more biomarkers selected from subset Y, wherein subset Y consists of biomarkers b2, b4-b20.

[0054] In another preferred embodiment, the set includes biomarkers b1-b3, b7, b16 and one or more biomarkers selected from subset Z, wherein subset Z is composed of biomarkers b4-b6, b8-b15, b17-b20.

[0055] In another preferred embodiment, the set includes biomarkers b1-b4, b7, b16-b17 and one or more biomarkers selected from subset Z, wherein subset Z is composed of biomarkers b5-b6, b8-b15, b18-b20.

[0056] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0057] b1-b4, b7, b16-b17.

[0058] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0059] b1-b3, b7, b16.

[0060] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0061] b1, b3.

[0062] In another preferred embodiment, the set includes biomarker b3 and one or more biomarkers selected from subset Y, wherein subset Y consists of biomarkers b1-b2 and b4-b20.

[0063] In another preferred embodiment, the set includes biomarkers b3-b4 and one or more biomarkers selected from subset Z, wherein subset Z consists of biomarkers b1-b2 and b5-b20.

[0064] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0065] b3-b4.

[0066] In another preferred embodiment, the set includes biomarkers selected from the following group:

[0067] b3.

[0068] In another preferred embodiment, the biomarker or biomarker set is derived from blood, plasma, or serum samples.

[0069] In another preferred embodiment, compared with a reference value, an increase in one or more biomarkers selected from subset H indicates that the subject has a risk of developing macular neovascular disease or suffers from macular neovascular disease.

[0070] Among them, subset H includes biomarkers b5, b6, b7, b11, b13, b14, b16, b17, and b19.

[0071] In another preferred embodiment, the subset H includes biomarkers b5, b7, b16, and b17.

[0072] In another preferred embodiment, the subset H includes biomarkers b5, b7, and b16.

[0073] In another preferred embodiment, the subset H includes biomarkers b5, b7, b11, b13, and b14.

[0074] In another preferred embodiment, the subset H includes biomarkers b5 and b7.

[0075] In another preferred embodiment, the subset H includes biomarkers b5, b7, b14, b16, b17, and b19.

[0076] In another preferred embodiment, the subset H includes biomarkers b7, b16, and b17.

[0077] In another preferred embodiment, the subset H includes biomarker b6.

[0078] In another preferred embodiment, compared with a reference value, a decrease in one or more biomarkers selected from subset K indicates that the subject has a risk of developing macular neovascular disease or suffers from macular neovascular disease.

[0079] Among them, subset K includes biomarkers b1, b2, b3, b4, b6, b8, b9, b10, b12, b15, b18, and b20.

[0080] In another preferred example, the subset K includes biomarkers b1, b2, b3, b4, and b6.

[0081] In another preferred embodiment, the subset H includes biomarkers b1, b2, and b3.

[0082] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, b6, b8, b9, b10, b12, and b15.

[0083] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, and b6.

[0084] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, b6, b9, b12, b18, and b20.

[0085] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, and b4.

[0086] In another preferred embodiment, the subset H includes biomarkers b3, b4, and b12.

[0087] In another preferred embodiment, the subset H includes biomarkers b3 and b4.

[0088] In another preferred embodiment, each biomarker is identified by mass spectrometry, preferably, by chromatography-mass spectrometry, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).

[0089] In another preferred embodiment, the set is used to assess the risk of a subject suffering from macular neovascularization disease or to diagnose a subject suffering from macular neovascularization disease.

[0090] In another preferred embodiment, the assessment of the subject's risk of developing macular neovascularization disease includes early screening for macular neovascularization disease.

[0091] In another preferred embodiment, the macular neovascularization disease includes age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological high myopia.

[0092] The second aspect of the present invention provides a reagent combination for assessing or diagnosing the risk of macular neovascularization disease, wherein the reagent combination comprises reagents for detecting each biomarker in the set described in the first aspect of the present invention.

[0093] In another preferred embodiment, the reagent includes a substance for detecting each biomarker in the set described in the first aspect of the present invention by mass spectrometry.

[0094] The third aspect of the present invention provides a kit, which includes the collection described in the first aspect of the present invention and / or the reagent combination described in the second aspect of the present invention.

[0095] In another preferred embodiment, each biomarker in the set described in the first aspect of the present invention is used as a standard.

[0096] In another preferred embodiment, the kit further comprises an instruction manual, which records a reference data set of the levels of each biomarker in the set as described in the first aspect of the present invention derived from patients with macular neovascular disease and / or healthy controls.

[0097] A fourth aspect of the present invention provides a use of a biomarker set for preparing a kit for assessing the risk of macular neovascularization disease in a subject to be tested or diagnosing macular neovascularization disease in a subject to be tested, wherein the biomarker set comprises one or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonucleolactone.

[0098] In another preferred embodiment, the macular neovascularization disease is selected from the group consisting of AMD, PVC, PM, or a combination thereof.

[0099] In another preferred embodiment, when used to assess the risk of AMD disease in a subject or diagnose AMD disease in a subject, the biomarker set includes biomarkers selected from the following group: L-sorbose, D-tagatose, or a combination thereof.

[0100] In another preferred embodiment, when used to assess the risk of AMD disease in a subject or diagnose AMD disease in a subject, the biomarker set also includes a biomarker selected from the following group: glycerol, L-2-amino-3-(1-pyrazolyl)propionic acid, 5-hydroxylysine, or a combination thereof.

[0101] In another preferred embodiment, when used to assess the risk of AMD disease in a test subject or diagnose AMD disease in a test subject, the biomarker set further includes a biomarker selected from the following group: ribonucleic acid lactone, petroselinic acid, or a combination thereof.

[0102] In another preferred embodiment, when used to assess the risk of AMD disease in a subject to be tested or to diagnose AMD disease in a subject to be tested, the biomarker set also includes a biomarker selected from the following group: hexanoic acid, 4-hydroxyphenylpyruvic acid, L-arabinose, L-glutamate, D-maltose, or a combination thereof.

[0103] In another preferred embodiment, when used to assess the risk of AMD disease in a subject or diagnose AMD disease in a subject, the biomarker set further includes a biomarker selected from the following group: pipecolic acid, maleic acid, oleic acid, hypoxanthine, linoleic acid, L-cysteine, or a combination thereof.

[0104] In another preferred embodiment, when used to assess the risk of a subject suffering from AMD disease or diagnose AMD disease in a subject, the biomarker set further includes biomarkers selected from Table 1.

[0105] In another preferred embodiment, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set comprises a biomarker selected from the following group: L-sorbose, ribonucleolactone, or a combination thereof.

[0106] In another preferred embodiment, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set further comprises a biomarker selected from the following group: petroselinic acid, D-tagatose, myristic acid, or a combination thereof.

[0107] In another preferred example, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set further includes a biomarker selected from the following group: heptadecanoic acid, L-2-amino-3-(1-pyrazolyl)propionic acid, or a combination thereof.

[0108] In another preferred example, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set further comprises a biomarker selected from the following group: α-ketoisovalerate, glycerol, 4-hydroxyphenylpyruvate, D-maltose, phenylpyruvate, 5-hydroxylysine, dodecanoic acid, or a combination thereof.

[0109] In another preferred embodiment, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set further includes a biomarker selected from the following group: palmitic acid, hypoxanthine, linoleic acid, stearic acid, pipecolic acid, pyruvic acid, or a combination thereof.

[0110] In another preferred embodiment, when used to assess the risk of a subject suffering from PVC disease or diagnose a subject suffering from PVC disease, the biomarker set further comprises biomarkers selected from Table 2.

[0111] In another preferred embodiment, when used to assess the risk of a PM disease in a subject or diagnose a PM disease in a subject, the biomarker set includes ribonucleotide.

[0112] In another preferred embodiment, when used to assess the risk of a PM disease in a subject or diagnose a PM disease in a subject, the biomarker set further includes L-2-amino-3-(1-pyrazolyl)propionic acid.

[0113] In another preferred embodiment, when used to assess the risk of PM disease in a subject or diagnose PM disease in a subject, the biomarker set further comprises a biomarker selected from the following group: glycerol, D-maltose, or a combination thereof.

[0114] In another preferred example, when used to assess the risk of PM disease in a subject to be tested or to diagnose PM disease in a subject to be tested, the biomarker set also includes biomarkers selected from the following group: pyruvate, hypoxanthine, linoleic acid, palmitic acid, oleic acid, petroselinic acid, stearic acid, maleic acid, or a combination thereof.

[0115] In another preferred embodiment, when used to assess the risk of PM disease in a subject or diagnose PM disease in a subject, the biomarker set further includes biomarkers selected from Table 3.

[0116] In another preferred embodiment, the evaluation or diagnosis comprises the steps of:

[0117] (1) providing a sample from a subject to be tested, and detecting the level of each biomarker in the set in the sample;

[0118] (2) comparing the level measured in step (1) with a reference data set or a reference value (such as a reference value for healthy controls);

[0119] Preferably, the reference data set includes the levels of each biomarker in the set from patients with macular neovascularization disease and healthy controls;

[0120] Preferably, the reference data set includes the levels of each biomarker in the set from AMD patients and healthy controls;

[0121] The reference data set includes the levels of each biomarker in the set from PVC disease patients and healthy controls;

[0122] The reference data set includes the levels of each biomarker in the set from PM patients and healthy controls.

[0123] In another preferred embodiment, the sample is selected from the group consisting of blood, plasma, and serum.

[0124] In another preferred embodiment, the step of comparing the level measured in step (1) with a reference data set also includes the step of establishing a multivariate statistical model to output the possibility of disease. Preferably, the multivariate statistical model is an orthogonal partial least squares regression discriminant analysis model.

[0125] In another preferred embodiment, if the disease probability is ≥ 0.5, the subject is determined to be at risk of or suffering from AMD disease.

[0126] In another preferred embodiment, when compared with a reference value, an increase in one or more biomarkers selected from subset H indicates that the subject has a risk of developing macular neovascularization disease or suffers from macular neovascularization disease.

[0127] Among them, subset H includes biomarkers b5, b6, b7, b11, b13, b14, b16, b17, and b19.

[0128] In another preferred embodiment, when compared with a reference value, an increase in one or more biomarkers selected from subset H indicates that the subject has a risk of AMD disease or suffers from AMD disease,

[0129] Among them, subset H includes biomarkers b5 and b7.

[0130] In another preferred example, the subset H also includes biomarkers b11, b13, and b14.

[0131] In another preferred embodiment, if the disease probability is ≥ 0.5, the subject is determined to be at risk of PCV disease or to suffer from PCV disease.

[0132] In another preferred embodiment, when compared with a reference value, an increase in one or more biomarkers selected from subset H indicates that the subject has a risk of PCV or suffers from PCV disease.

[0133] Among them, subset H includes biomarkers b7, b16, b17, and b19.

[0134] In another preferred example, the subset H also includes biomarkers b5 and b14.

[0135] In another preferred embodiment, if the disease probability is ≥ 0.5, the subject is determined to have a PM disease risk or suffer from a PM disease.

[0136] In another preferred embodiment, when compared with a reference value, an increase in one or more biomarkers selected from subset H indicates that the subject has a risk of PM or suffers from PM disease.

[0137] Among them, subset H includes biomarker b6.

[0138] In another preferred embodiment, compared with a reference value, a decrease in one or more biomarkers selected from subset K indicates that the subject has a risk of developing macular neovascularization disease or suffers from macular neovascularization disease.

[0139] Among them, subset K includes biomarkers b1, b2, b3, b4, b6, b8, b9, b10, b12, b15, b18, and b20.

[0140] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, and b6.

[0141] In another preferred embodiment, the subset H includes biomarkers b1, b2, and b3.

[0142] In another preferred embodiment, compared with a reference value, a decrease in one or more biomarkers selected from subset K indicates that the subject to be tested has a risk of AMD or suffers from AMD.

[0143] Among them, subset K includes biomarkers b1, b2, b3, b4, b6, b8, b9, b10, b12, and b15.

[0144] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, and b6.

[0145] In another preferred embodiment, the subset H includes biomarkers b1, b2, and b3.

[0146] In another preferred embodiment, compared with a reference value, a decrease in one or more biomarkers selected from subset K indicates that the subject to be tested has a risk of PCV or suffers from PCV disease.

[0147] Among them, subset K includes biomarkers b1, b2, b3, b4, b6, b9, b12, b18, and b20.

[0148] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, and b4.

[0149] In another preferred embodiment, the subset H includes biomarkers b1, b2, and b3.

[0150] In another preferred embodiment, compared with a reference value, a decrease in one or more biomarkers selected from subset K indicates that the subject has a risk of PM or suffers from PM disease.

[0151] Among them, subset K includes biomarkers b3, b4, and b12.

[0152] In another preferred embodiment, the subset H includes biomarkers b3 and b4.

[0153] In another preferred embodiment, the subset H includes biomarker b3.

[0154] In another preferred embodiment, the level of each biomarker is detected by mass spectrometry, preferably by chromatography-mass spectrometry, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).

[0155] In another preferred embodiment, before step (1), the method further comprises the step of processing the sample.

[0156] A fifth aspect of the present invention provides a method for assessing the risk of a subject suffering from macular neovascularization disease or diagnosing a subject suffering from macular neovascularization disease, comprising the steps of:

[0157] (1) providing a sample from a subject to be tested, and detecting the level of each biomarker in a set in the sample, wherein the set includes one or more biomarkers selected from the group consisting of L-sorbose, D-tagatose, and ribonucleolactone;

[0158] (2) comparing the level measured in step (1) with a reference data set or a reference value (such as a reference value for healthy controls);

[0159] Preferably, the reference data set includes the levels of each biomarker in the set from patients with macular neovascularization disease and healthy controls.

[0160] In another preferred embodiment, the reference data set includes the levels of each biomarker in the set from AMD disease patients and healthy controls.

[0161] In another preferred embodiment, the reference data set includes the levels of each biomarker in the set from PCV disease patients and healthy controls.

[0162] In another preferred embodiment, the reference data set includes the levels of each biomarker in the set from PM disease patients and healthy controls.

[0163] A sixth aspect of the present invention provides a method for screening candidate compounds for treating macular neovascularization disease, comprising the steps of:

[0164] (1) In the test group, a test compound is administered to the subject to be tested, and the level V1 of each biomarker in the set in the sample derived from the subject in the test group is detected; in the control group, a blank control (including a solvent) is administered to the subject to be tested, and the level V2 of each biomarker in the set in the sample derived from the subject in the control group is detected;

[0165] (2) comparing the level V1 and the level V2 detected in the previous step to determine whether the test compound is a candidate compound for treating macular neovascularization disease, wherein the set includes one or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonucleic acid lactone.

[0166] In another preferred embodiment, the subject to be tested is a patient with macular neovascularization disease.

[0167] In another preferred embodiment, if the level V1 of one or more biomarkers selected from subset H is significantly lower than the level V2, it indicates that the test compound is a candidate compound for treating macular neovascularization disease.

[0168] Among them, subset H includes biomarkers b5, b6, b7, b11, b13, b14, b16, b17, and b19.

[0169] In another preferred embodiment, the subset H includes biomarkers b5, b7, b16, and b17.

[0170] In another preferred embodiment, the subset H includes biomarkers b5, b7, and b16.

[0171] In another preferred embodiment, the “significantly lower than” refers to a ratio of level V1 / level V2 of ≤0.8, preferably ≤0.6, and more preferably, ≤0.4.

[0172] In another preferred embodiment, if the level V1 of one or more biomarkers selected from subset K is significantly higher than the level V2, it indicates that the test compound is a candidate compound for treating macular neovascularization disease.

[0173] Among them, subset K includes biomarkers b1, b2, b3, b4, b6, b8, b9, b10, b12, b15, b18, and b20.

[0174] In another preferred embodiment, the subset H includes biomarkers b1, b2, b3, b4, and b6.

[0175] In another preferred embodiment, the subset H includes biomarkers b1, b2, and b3.

[0176] In another preferred embodiment, the “significantly higher than” refers to a ratio of level V1 / level V2 of ≥1.2, preferably ≥1.5, and more preferably, ≥1.8.

[0177] The seventh aspect of the present invention provides a use of a biomarker set for screening candidate compounds for treating macular neovascular disease and / or for evaluating the therapeutic effects of candidate compounds on macular neovascular disease, wherein the biomarker set includes one or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonucleolactone.

[0178] An eighth aspect of the present invention provides a method for establishing a mass spectrometry model for assessing the risk of macular neovascular disease or for diagnosing macular neovascular disease, the method comprising the step of identifying differentially expressed substances in blood samples between patients and healthy controls, wherein the differentially expressed substances include one or more biomarkers in a biomarker set, wherein the biomarker set includes one or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonucleolactone.

[0179] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0180] Figure 1 The demographic and clinical characteristics of this study are shown.

[0181] Figure 2 The principal component analysis score plots for the first two and three principal components for the age-related macular degeneration group and the cataract group are shown.

[0182] Figure 3 The orthogonal partial least squares discriminant analysis score plots and 200 permutation test results of the model for the age-related macular degeneration group and the control group are shown.

[0183] Figure 4 Metabolic markers for the three subtypes of macular neovascular disease are shown.

[0184] Figure 4 A is a heat map of different metabolic markers for different macular neovascular diseases, where the color changes from blue to brown indicate an increase in metabolic markers; Figure 4 B is a Venn diagram of metabolic markers related to three disease subtypes: age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological high myopia; Figure 4 C is the score plot of the sparse partial least squares discriminant analysis model based on 131 metabolic markers.

[0185] Figure 5 ROC curve analysis based on the metabolic marker panel. Figure 5 A is the ROC curve analysis between the AMD group and the control group; Figure 5 B is the ROC curve analysis between the PCV group and the control group; Figure 5 C is the ROC curve analysis between the PM group and the control group. DETAILED DESCRIPTION

[0186] After extensive and in-depth research, the inventor unexpectedly discovered a biomarker for macular neovascular disease for the first time. Specifically, the inventor discovered a biomarker set, which includes multiple biomarkers for macular neovascular disease, which can be used to assess the risk of macular neovascular disease in a subject to be tested or to diagnose macular neovascular disease in a subject to be tested, and has the advantages of high sensitivity and high specificity, and has important application value. On this basis, the inventor completed the present invention.

[0187] the term

[0188] The terms used in the present invention have the meanings commonly understood by those of ordinary skill in the relevant art. However, in order to better understand the present invention, some definitions and related terms are explained as follows:

[0189] According to the present invention, the term "macular neovascular disease" refers to a group of diseases characterized by choroidal neovascularization in the macular area, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and pathological high myopia (PM). AMD is often manifested as drusen and retinal pigment epithelial damage. PCV is a macular disease with a high incidence in Asian populations, characterized by orange-red nodular lesions under the retina and abnormal branching choroidal vascular networks and polypoidal choroidal vascular dilation foci at their ends shown by indocyanine green angiography. The pathological characteristics of PM include lacquer cracks, flaky atrophy, thinning of the choroid and choroidal capillaries, etc.

[0190] As used herein, the terms "BCVA" and "best corrected visual acuity" are used interchangeably and refer to best corrected visual acuity.

[0191] As used herein, the terms "CRT" and "central retinal thickness" are used interchangeably and refer to the central retinal thickness.

[0192] As used herein, the terms "CRV" and "central retinal volume" are used interchangeably and refer to the central retinal volume.

[0193] According to the present invention, the term "biomarker panel" refers to one biomarker, or a combination of two or more biomarkers.

[0194] According to the present invention, mass spectrometry (MS) can be divided into ion trap mass spectrometry, quadrupole mass spectrometry, orbital trap mass spectrometry and time-of-flight mass spectrometry, with deviations of 0.2amu, 0.4amu, 3ppm and 5ppm respectively. In the present invention, time-of-flight mass spectrometry is used to obtain MS data.

[0195] According to the present invention, the level of a biomarker substance is indicated by a value normalized by the mass spectrometry signal area.

[0196] According to the present invention, the reference set refers to the training set.

[0197] According to the present invention, it is known from the prior art that the training set and the validation set have the same meaning. In one embodiment of the present invention, the training set refers to a set of biomarker levels in biological samples of CHD patients and healthy controls. In one embodiment of the present invention, the validation set refers to a data set used to test the performance of the training set. In one embodiment of the present invention, the level of the biomarker can be represented as an absolute value or a relative value according to the method of determination. For example, when the level of the biomarker is determined by mass spectrometry, the intensity of the peak can represent the level of the biomarker, which is a relative value level; when the level of the biomarker is determined by PCR, the number of copies of the gene or the number of copies of the gene fragment can represent the level of the biomarker.

[0198] In one embodiment of the present invention, the reference value refers to the reference value or normal value of a healthy control. It is clear to those skilled in the art that, when the number of samples is sufficient, the range of normal values ​​(absolute values) of each biomarker can be obtained by inspection and calculation methods. Therefore, when other methods other than mass spectrometry are used to detect the levels of biomarkers, the absolute values ​​of the levels of these biomarkers can be directly compared with normal values ​​to evaluate the risk of suffering from macular neovascular disease (especially age-related macular degeneration, polypoidal choroidal vasculopathy and pathological high myopia), as well as to diagnose or early diagnose macular neovascular disease (especially age-related macular degeneration, polypoidal choroidal vasculopathy and pathological high myopia). In the present invention, statistical methods can also be used.

[0199] According to the present invention, the term "biomarker", also known as "biological marker", refers to a measurable indicator of a biological state of an individual. Such biomarkers can be any substance in an individual as long as they are related to a specific biological state (e.g., disease) of the individual being tested, for example, nucleic acid markers (e.g., DNA), protein markers, cytokine markers, chemokine markers, carbohydrate markers, antigen markers, antibody markers, species markers (species / genus markers) and functional markers (KO / OG markers), etc. Biomarkers are measured and evaluated, often to examine normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions, and are useful in many scientific fields.

[0200] According to the present invention, the term "subject" refers to an animal, particularly a mammal, such as a primate, preferably a human.

[0201] According to the present invention, the term "plasma" refers to the liquid component of whole blood. Depending on the separation method used, plasma may be completely free of cellular components or may contain varying amounts of platelets and / or small amounts of other cellular components.

[0202] According to the present invention, terms such as "a", "an" and "the" refer not only to the singular individual but include the general class that may be used to describe a particular embodiment.

[0203] It should be noted that the explanations of the terms provided herein are only for enabling those skilled in the art to better understand the present invention and are not intended to limit the present invention.

[0204] Evaluation Methodology

[0205] The present invention calculates the weighted comprehensive score by the formula S=W1S1+W2S2+WiS3+…WnSn;

[0206] Among them, W1, W2...Wn are weights;

[0207] S1, S2, ... Sn are the scores of each marker.

[0208] In a preferred embodiment, the S of the normal population subject =W1S1+W2S2+WiS3+…WnSn.

[0209] S in susceptible populations subject '=W1'S1'+W2'S2'+Wi'S3'+...Wn'Sn'.

[0210] The settings are: normal = 0, abnormal = 1.

[0211] When Fold change>predetermined threshold value (such as 1.2, 1.5, 1.8), it is recorded as abnormal; or when Fold change<predetermined threshold value (such as 0.8, 0.6, 0.4), it is recorded as abnormal.

[0212] The results showed that compared with the normal population, S subject In comparison, when the susceptible population's S subject 'Significantly higher than that of normal people subject , indicating a risk of disease.

[0213] The results show that the markers of the present invention can significantly improve the accuracy of diagnosis of macular neovascularization diseases (especially AMD, PCV, PM).

[0214] The main advantages of the present invention include:

[0215] (a) The present invention uses plasma metabolites as biomarkers for early screening, prediction, prevention and treatment of macular neovascular diseases (especially age-related macular degeneration, polypoidal choroidal vasculopathy and pathological high myopia), which has the advantages of high sensitivity and high specificity and has important application value.

[0216] (b) Plasma as a biomarker detection sample has the advantages of easy collection, simple operation steps and continuous in vitro detection.

[0217] (c) The biomarkers of the present invention are used for early screening, prognosis, prevention and treatment of macular neovascular diseases (especially age-related macular degeneration, polypoidal choroidal vasculopathy and pathological high myopia) with good repeatability.

[0218] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0219] Unless otherwise specified, the reagents and materials used in the examples of the present invention are all commercially available products.

[0220] Example 1

[0221] Patient recruitment

[0222] A total of 328 patients were recruited from the Eye Center of Shanghai First People's Hospital, including 24.7% (81) controls, 26.8% (88) patients with age-related macular degeneration, 31.1% (102) patients with polypoidal choroidal vasculopathy, and 17.4% (57) patients with pathological high myopia. All patients underwent OCT to measure macular thickness and volume.

[0223] Results Figure 1 , demographic and clinical characteristics of this study.

[0224] Example 2

[0225] Metabolomic manifestations of macular neovascular disease subtypes

[0226] Gas chromatography-time of flight mass spectrometry was used to perform metabolomics analysis on blood samples from the control group and patients with three different subtypes of macular neovascularization, and a total of 131 metabolites were identified. Pattern recognition technology was also used to further clarify the metabolic phenotypes of the three different subtypes of macular neovascularization.

[0227] Results Figure 2-4 . Figure 2 : The principal component analysis scores of the first two and three principal components of the age-related macular degeneration group and cataract group. The samples of the AMD group and the control group have a certain separation trend in the score graph, indicating that there are differences in the overall metabolism between AMD and the control group. Figure 3 The orthogonal partial least squares discriminant analysis (OPLSDA) score graph of the age-related macular degeneration group and the control group and the results of 200 permutation tests of the model are shown. On the OPLSDA score graph, AMD and the control group are completely separated, and the results of 200 permutation tests show that the OPLSDA model fits well without overfitting. Figure 4 Metabolic markers for the three subtypes of macular neovascular disease are shown. Figure 4 A is a heat map of different metabolic markers for different macular neovascular diseases, where the color changes from blue to brown indicate an increase in metabolic markers; Figure 4 B is a Venn diagram of metabolic markers related to three disease subtypes: age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological high myopia; Figure 4 C is the score graph of the sparse partial least squares discriminant analysis model based on 131 metabolite markers. Table 1: Metabolites with statistical differences between the macular neovascular disease group and the control group. Figure 5 A is the ROC curve analysis result of the AMD group and the control group based on the metabolic marker group, with an AUC value of 0.967, a specificity of 89.8%, and a sensitivity of 95.1%; Figure 5B is the ROC curve analysis result of the PCV group and the control group based on the metabolic marker group, with an AUC value of 0.959, a specificity of 87.3%, and a sensitivity of 92.6%; Figure 5 C is the ROC curve analysis result of the PM group and the control group based on the metabolite marker group, with an AUC value of 0.916, a specificity of 78.9%, and a sensitivity of 90.1%. The ROC curve analysis results show that the metabolite marker group obtained based on the plasma metabolome study has a good effect in distinguishing macular neovascular disease from the control.

[0228] Table 4 New metabolites with statistically significant differences between the AMD group and the control group

[0229]

[0230]

[0231] Table 5 New metabolites with statistically significant differences between the PCV group and the control group

[0232]

[0233]

[0234] Table 6 New metabolites with statistically significant differences between the PM group and the control group

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243] Table 8 Prediction rates of AMD, PM, and PCV (taking ribonucleic acid lactone as an example)

[0244]

[0245] Table 9 Prediction rates of AMD, PM, and PCV (taking D-tagatose as an example)

[0246]

[0247]

[0248] Table 10 Prediction rates of AMD, PM and PCV (taking sorbitol as an example)

[0249]

[0250] The data in Tables 4 to 10 show that, in the present invention, the use of a single marker, such as ribonucleolactone, sorbitol, and D-tagatose, can greatly improve the prediction rate of macular neovascularization disease.

[0251] Therefore, the combination of the markers of the present invention can improve the accuracy of diagnosis of macular neovascularization disease.

[0252] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. Use of a reagent combination in the preparation of a kit for risk assessment or diagnosis of macular neovascularization disease, wherein: The reagent combination includes reagents for detecting biomarkers in a set, and the set includes two or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonolactone.

2. The use according to claim 1, characterized in that The set further includes two or more biomarkers selected from biomarkers b3 to b20: 。 3. The use according to claim 2, characterized in that The set includes biomarkers b1 to b20.

4. The use according to claim 1, characterized in that The macular neovascular disease is selected from the group consisting of AMD, PVC, PM, or a combination thereof.

5. A method for establishing a mass spectrometry model for assessing the risk of macular neovascularization disease or for diagnosing macular neovascularization disease, characterized in that: The method includes the step of identifying differentially expressed substances in blood samples between patients and healthy controls, wherein the differentially expressed substances include biomarkers in one or more biomarker sets, wherein the biomarker set includes one or more biomarkers selected from the following group: L-sorbose, D-tagatose and ribonucleic acid lactone.

Citation Information

Patent Citations

  • Cosmetic composition for improving health of scalp and method of preparing the same

    CN107440928A